Cancidas and Cell death - a phase IV clinical study of FDA data

Summary:

Cell death is reported as a side effect among people who take Cancidas (caspofungin acetate), especially for people who are female, 0-1 old, have been taking the drug for < 1 month also take Vancomycin, and have Escherichia test positive.

The study is created by eHealthMe based on reports of 4,868 people who have side effects when taking Cancidas from the FDA, and is updated regularly.

What is Cancidas?

Cancidas has active ingredients of caspofungin acetate. eHealthMe is studying from 4,879 Cancidas users. Check the latest studies of Cancidas.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

4,868 people reported to have side effects when taking Cancidas.
Among them, 12 people (0.25%) died.

Among these 12 people:

How long have people been on Cancidas when they died? *

What is the gender of people who died when taking Cancidas? *

female: 75 %
male: 25 %

What is the age of people who died when taking Cancidas? *

What are other drugs people take besides Cancidas? *

What are other side effects people have before they died? *

Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 11 people, 91.67%
Thrombocytopenia (decrease of platelets in blood): 7 people, 58.33%
Urination - Excessive Volume: 6 people, 50.00%
Diarrhea: 6 people, 50.00%
Haemodynamic Instability (disturbances in the blood movement in our body): 6 people, 50.00%
Haematoma (collection of blood outside the blood vessels): 6 people, 50.00%
Gastrointestinal Pain: 6 people, 50.00%
Gallstones (stone formation by bile component): 6 people, 50.00%
Gallbladder Enlargement: 6 people, 50.00%
Fluid Overload (too much fluid in the blood): 6 people, 50.00%

What are the existing conditions these people have? *

Immunodeficiency Disorders: 6 people, 50.00%
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 6 people, 50.00%
High Blood Pressure: 6 people, 50.00%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 6 people, 50.00%
Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 6 people, 50.00%
Escherichia Test Positive: 6 people, 50.00%
Lung Disorder (lung disease): 1 person, 8.33%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 1 person, 8.33%
Fusarium Infection (fungal infection): 1 person, 8.33%
Fever: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cancidas:

Cancidas (4,879 reports)

Expand to all the drugs that have ingredients of caspofungin acetate:

Cell death and drugs with ingredients of caspofungin acetate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cancidas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cell death:

Cell death (210 drugs)

Browse all the conditions that are associated with Cell death:

Cell death (331 conditions)

Related publications that referenced our studies

Biswal S, "Complete heart block in a neutropenic patient with aspergillosis: An unusual adverse effect of caspofungins", Journal of pharmacology & pharmacotherapeutics, 2012 Jan .
Biswal S, "Complete heart block in a neutropenic patient with aspergillosis: An unusual adverse effect of caspofungins", Journal of pharmacology & pharmacotherapeutics, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on caspofungin acetate (the active ingredients of Cancidas) and Cancidas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.